Rapport Therapeutics (NASDAQ:RAPP) Shares Up 5.7% – Here’s What Happened

Rapport Therapeutics (NASDAQ:RAPP) shot up 5.7% on Wednesday . The company traded as high as $20.16 and last traded at $20.16. 7,396 shares were traded during mid-day trading, a decline of 95% from the average session volume of 152,312 shares. The stock had previously closed at $19.07.

Rapport Therapeutics Price Performance

The stock has a 50-day simple moving average of $23.05.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new stake in Rapport Therapeutics in the third quarter valued at approximately $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $34,000. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at $101,000. Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter valued at $116,000. Finally, MetLife Investment Management LLC bought a new position in Rapport Therapeutics during the third quarter worth $117,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.